ZUMA-7: What the Lymphoma Trial Found

When the first treatment does not hold

Large B-cell lymphoma is usually treated with chemoimmunotherapy, and most people do well. The trouble starts with the group that does not.

If the lymphoma never responds, or comes back within a year, the outlook has been poor. The published report opens by saying exactly that.

The long-standing second step was salvage chemoimmunotherapy, then, for those whose disease responded, high-dose chemotherapy with an autologous stem-cell transplant using the person's own blood-forming cells. It works for some people. It requires responding to the salvage chemotherapy first, and many never get that far.

ZUMA-7 tested replacing that whole sequence with a single CAR T-cell infusion.

What CAR T-cell therapy is

T cells are the immune system's killers. In some people they simply do not recognize the lymphoma.

CAR T-cell therapy takes that person's own T cells out of the blood, and engineers them in a laboratory to carry a chimeric antigen receptor — a synthetic docking clamp that grips a specific target. In axicabtagene ciloleucel, the target is CD19, a protein on the surface of B cells.

The modified cells are multiplied and infused back. They then hunt B cells, including the cancerous ones. Our page on lymphoma explains where these cancers come from.

Trial at a glance

Field	Detail
Trial	ZUMA-7
Registry number	NCT03391466
Phase	3, randomized, international
Participants	359
Allocation	1:1 — 180 to axicabtagene ciloleucel, 179 to standard care
Population	Large B-cell lymphoma refractory to, or relapsed within 12 months of, first-line chemoimmunotherapy
Comparison	CAR T-cell therapy versus salvage chemoimmunotherapy then transplant in responders
Main measure	Event-free survival, by blinded central review

Event-free survival counts the time until the disease progresses, treatment fails, a new treatment starts, or the person dies. It is a stricter measure than progression alone, because starting something else counts as an event.

The two-year result

At a median follow-up of 24.9 months, median event-free survival was 8.3 months with CAR T against 2.0 months with standard care. At 24 months, 41 percent versus 16 percent were event-free.

The hazard ratio was 0.40, with a 95 percent confidence interval of 0.31 to 0.51 and P<0.001. Roughly a 60 percent lower risk of an event at any point.

Tumors responded in 83 percent versus 50 percent, with complete responses in 65 percent versus 32 percent.

The five-year survival result

Trials that improve a scan measure often fail to change how long people live. This one was followed up to check.

The prespecified overall survival analysis, reported at five years after the first randomization, found deaths in 82 of the CAR T group and 95 of the standard-care group. At a median follow-up of 47.2 months, median overall survival had not been reached in the CAR T group, against 31.1 months with standard care. Estimated four-year overall survival was 54.6 percent versus 46.0 percent.

The hazard ratio for death was 0.73, with an interval of 0.54 to 0.98 and P=0.03.

"Not reached" means more than half the group was still alive when the analysis was done, so no midpoint could be calculated.

What it costs

Grade 3 or higher adverse events occurred in 91 percent of the CAR T group and 83 percent of the standard-care group.

Two side effects are specific to CAR T. Cytokine release syndrome is a storm of immune signaling molecules, causing fever, low blood pressure, and low oxygen; severe cases affected 6 percent. Neurologic events, which can include confusion, tremor, difficulty speaking, and seizures, were severe in 21 percent. The report notes no deaths from either.

Both are managed in centers set up for it, which is part of why CAR T is not available everywhere.

Symptoms that mean a call, not a wait

Anyone on treatment for lymphoma, and anyone worried about lymphoma, should know the pattern.

• A painless swollen gland in the neck, armpit, or groin lasting more than two or three weeks.
• Drenching night sweats that soak nightclothes or sheets.
• Fever with no infection to account for it.
• Weight loss of more than about a tenth of your body weight without trying.
• After CAR T specifically: fever, confusion, difficulty finding words, or unusual drowsiness. These are urgent and need the treating center, not a walk-in clinic.

What this trial cannot tell you

• Everyone here had lymphoma that failed first-line treatment or came back within 12 months. It says nothing about later relapses or about first-line care.
• Median event-free survival of 8.3 months in the better arm sounds short because the measure is strict. The two-year and four-year figures carry more meaning.
• The comparison was salvage chemotherapy then transplant. Second-line practice has continued to move since.
• Severe neurologic events in 21 percent is a substantial number, and access requires a center with the expertise to handle them.
• SEER, the federal cancer surveillance program, records five-year relative survival for non-Hodgkin lymphoma at 74.3 percent overall, across many different subtypes. That is a group average from people diagnosed years ago, and it describes populations rather than individuals. Our page on what standard of care means in a trial explains why a control arm dates.

Sources

• N Engl J Med 2022: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7), PMID 34891224 — record retrieved via NCBI eutils
• N Engl J Med 2023: Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma, PMID 37272527 — record retrieved via NCBI eutils
• ClinicalTrials.gov API v2 record for NCT03391466
• NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.